Antihelminthics Market Share

The market for anthelmintics is expected to expand as helminth illnesses brought on by roundworm, whipworm, hookworm, and other worms become more common. Helminth diseases are spread through the soil by numerous parasitic worm species. 

As of March 2020, the WHO estimates that over 1.5 billion people globally had helminth infections that were spread through the soil. Some of the main disease-causing species of hookworms include Ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale. Additionally, it is estimated that S. stercoralis causes harm to 600 million people worldwide. Poor sanitation and hygiene are other factors that contribute to the rise in soil-transmitted helminth infections.

The increasing cost of healthcare contributes to the development of the market for anthelmintics and is a crucial element determining its growth rate. The market dynamics would be further impacted by various government organisations' efforts to strengthen the healthcare infrastructure by boosting funding.

The market for anthelmintic drugs is anticipated to grow as a result of government initiatives and a paradigm shift towards assisting in the management of helminth diseases globally. For instance, the National Deworming Day is a significant effort to eradicate worms in India by the Ministry of Health and Family Welfare. The WHO estimates that 241 million Indian children between the ages of one and 14 are susceptible to parasitic intestinal worms. 

Government suggestions to increase awareness and eradicate helminth infection are therefore anticipated. Additionally, the market for anthelmintics will grow due to the world's ageing population and rise in the number of infected patients. Favourable reimbursement policies will also accelerate the market's expansion.

The development of anthelmintic medications that can cure nematodes using plant-based materials is receiving a lot of attention. Intestinal parasite nematodes are currently a severe problem in both humans and animals. Animals therefore account for a larger revenue share than humans in the market for anthelmintic medications, which is expected to grow at a CAGR of 5% over the course of the forecast period.

Pharmaceutical firms face a hurdle due to anthelmintic medication resistance in both people and animals. As a result, businesses are harnessing components from medicinal plants to develop new anthelmintic medications. 

The Global Antihelminthics Market Industry is poised for substantial growth, with projections indicating a market value of 1.74 USD Billion in 2024 and an anticipated increase to 4.47 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 8.95% from 2025 to 2035. The factors driving this expansion include rising prevalence of helminth infections, government initiatives, advancements in drug development, and increased awareness. These elements collectively contribute to a robust market outlook, reflecting the critical need for effective antihelminthic treatments in both human and veterinary medicine.

The expanding use of antihelminthic drugs in veterinary medicine is emerging as a notable driver for the Global Antihelminthics Market Industry. As pet ownership increases globally, the demand for effective deworming treatments for pets and livestock is rising. This trend is particularly evident in developed countries, where pet owners are becoming more proactive about their animals' health. The veterinary segment is projected to contribute significantly to the overall market growth, as it encompasses a wide range of antihelminthic products tailored for various animal species. This diversification in applications is likely to enhance the market's resilience and adaptability.

Innovations in drug development play a crucial role in shaping the Global Antihelminthics Market Industry. The emergence of novel antihelminthic agents, which are more effective and exhibit fewer side effects, is likely to attract attention from healthcare providers and patients alike. Research institutions and pharmaceutical companies are increasingly focusing on developing combination therapies that target multiple helminth species simultaneously. This trend not only enhances treatment efficacy but also addresses the issue of drug resistance. As a result, the market is expected to grow at a compound annual growth rate of 8.95% from 2025 to 2035, indicating a robust future for antihelminthic innovations.

Heightened awareness and education regarding helminth infections significantly contribute to the growth of the Global Antihelminthics Market Industry. Public health campaigns aimed at educating communities about the transmission and prevention of these infections are gaining traction. Such initiatives encourage individuals to seek treatment and preventive measures, thereby increasing the demand for antihelminthic medications. Additionally, healthcare professionals are being trained to recognize and address helminth infections effectively. This growing awareness is expected to drive the market value to 1.74 USD Billion in 2024, as more individuals seek treatment options and preventive strategies.

Government initiatives aimed at controlling and eliminating helminth infections significantly influence the Global Antihelminthics Market Industry. Various countries are implementing national programs to provide free or subsidized antihelminthic treatments, particularly in endemic regions. For instance, the World Health Organization's preventive chemotherapy strategy encourages mass drug administration, which has been shown to reduce infection rates. Such initiatives not only enhance accessibility to treatments but also stimulate market growth. The anticipated increase in market value to 4.47 USD Billion by 2035 reflects the positive impact of these government efforts on the antihelminthic sector.

The increasing incidence of helminth infections globally is a primary driver for the Global Antihelminthics Market Industry. According to the World Health Organization, approximately 1.5 billion people are infected with soil-transmitted helminths, particularly in tropical and subtropical regions. This widespread prevalence necessitates effective antihelminthic treatments, thereby propelling market growth. As awareness of these infections rises, governments and health organizations are likely to invest more in antihelminthic therapies, contributing to the projected market value of 1.74 USD Billion in 2024. The urgency to address these health challenges indicates a sustained demand for antihelminthic medications.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Antihelminthics Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Antihelminthics Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Antihelminthics Industry to benefit clients and increase the market sector. In recent years, the Antihelminthics Industry has offered some of the most significant advantages to medicine. 

Major players in the Antihelminthics Market, including Abbott, Novartis AG, ZEISS International , Johnson & Johnson Services, Inc., Sanofi, Merck & Co., Inc., GlaxoSmithKline plc., Astellas Pharma Inc., Bayer AG, Mentis Pharma Ltd., Pfizer Inc., Sanofi, ALLERGAN, and AstraZeneca, are attempting to increase market demand by investing in research and development operations.

With a focus on livestock and companion animals, Zoetis Inc. (Zoetis) is an animal healthcare firm that researches, develops, produces, and sells animal health medications, vaccinations, and diagnostic tools. Biodevices, genetic diagnostics, and precision livestock husbandry are used to supplement its goods. The business, among other things, sells vaccines, parasiticides, anti-infective treatments, and medicated feed additives. Through its client supply services (CSS) organisation, it also provides contract manufacturing services to other parties. 

The company has manufacturing sites all around the world, and it sells goods through direct marketing channels and distributors in the Americas, Europe, Africa, Asia, and Australia to veterinarians, livestock producers, as well as people who raise and care for farm and companion animals. The U.S. city of Parsippany, New Jersey, serves as the company's headquarters. Simparica Trio, a medication combination used to prevent heartworm disease, roundworms, rickets, hookworms, and fleas in dogs, was approved by the FDA in February 2020 for Zoetis.

A pharmaceutical firm that develops, produces, promotes, and distributes pharmaceutical drugs is Amneal Pharmaceuticals Inc. (Amneal), originally Amneal Pharmaceuticals LLC. Pharmaceutical products that are offered by it are both generic and specialised. The company also sells products for oncology, inflammation and pain, central nervous system illnesses, endocrinology, and parasite infections, such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution, and Pyridiu. 

Amneal provides goods in a range of dosage forms, including oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids, and other device-driven goods. India, Switzerland, Ireland, and the United Kingdom are all operating hubs for the business. 

The American city of Bridgewater is where Amneal is headquartered. Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. successfully merged in May 2018 to create Amneal Pharmaceuticals, Inc. The generic industry is anticipated to benefit from this deal, making Amneal the fifth-largest generic company in the United States.